

Pteridine Nucleosides Analogs of 2'-Deoxyadenosine as Building Blocks for Oligonucleotide Synthesis

Oliver Jungmann & Wolfgang Pfeleiderer

To cite this article: Oliver Jungmann & Wolfgang Pfeleiderer (1997) Pteridine Nucleosides Analogs of 2'-Deoxyadenosine as Building Blocks for Oligonucleotide Synthesis, *Nucleosides and Nucleotides*, 16:5-6, 863-868, DOI: [10.1080/07328319708002964](https://doi.org/10.1080/07328319708002964)

To link to this article: <http://dx.doi.org/10.1080/07328319708002964>



Published online: 22 Aug 2006.



Submit your article to this journal [↗](#)



Article views: 13



View related articles [↗](#)



Citing articles: 2 View citing articles [↗](#)

PTERIDINE NUCLEOSIDES ANALOGS OF 2'-DEOXYADENOSINE AS BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS


Oliver Jungmann and Wolfgang Pfeleiderer*

Fakultät für Chemie, Universität Konstanz, Postfach 5560, D-78434 Konstanz, Germany


ABSTRACT. The synthesis, configuration and conformation of adenosine analogous pteridine nucleosides and their conversion into the monomeric building blocks for the automated application in an DNA synthesizer is described.

Introduction. Oligonucleotide probes containing fluorophores are increasingly used to study intra- and intermolecular interactions regarding energy-transfer phenomena, hybridisation and stacking effects in oligonucleotide and nucleic acid chemistry. Fluorophores are very sensitive and reflect changes in their immediate environment through measurable differences in fluorescence properties.


Pteridines are well known for their strong fluorescence and have been considered as an alternative possibility to label oligonucleotides, although these heterocyclic ring systems reveal some difficulties from a synthetic and chemical point of view.



2'-Deoxyadenosine



4-Amino-8-(2-deoxy- β -D-ribofuranosyl)-7(8H)-pteridinones



Monomeric building blocks for oligonucleotide synthesis

Pteridine nucleosides can be regarded as structural analogs of the naturally occurring pyrimidine and purine nucleosides, respectively, and were therefore synthesized in our laboratories since 1970, expecting some biological activity. However, so far no antibacterial,

antiviral or antitumor activity was found. The physical properties of these compounds are still of interest due to the fluorescence of the nucleobases.

The high quantum yields of 4-amino-7(8H)-pteridinone derivatives called our attention to the synthesis of the 7(8H)-pteridinone-N(8)-2'-deoxy- β -D-ribonucleosides in a dimethoxytrityl, phosphoramidite form, which can be site-specifically inserted into oligonucleotides through a 3',5'-phosphodiester linkage using an automated approach on solid support material in a DNA synthesizer. The 4-amino pteridinones show a close relationship to 2'-deoxyadenosine and offer their application for the formation of modified oligonucleotides to a real time assay for the HIV-1 integrase 3'-processing reaction¹.


Synthesis. Recently we published a new efficient method which allows the regio- and stereospecific synthesis of 7(8H)-pteridinone-N(8)-2'-deoxy- β -D-ribonucleosides². In this way the 4-amino- as well as the 4-dimethylaminomethyleneamino-7(8H)-pteridinone derivatives react in form of their DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) salts in a clean S_N2 -type mechanism with 3,5-di-O-(4-chlorobenzoyl)-1-chloro-2-deoxy- α -D-ribofuranose to the 4-amino- (**1-6**) and 4-dimethylaminomethyleneamino-8-(2-deoxy- β -D-ribofuranosyl)-7(8H)-pteridinones (**7-9**), respectively, by low formation of the corresponding α -anomers.

In accordance to G. Zemplen³ the treatment of the compounds (**1-6**) with sodium methoxide or potassium carbonate in methanol resulted in the cleavage of the sugar protecting groups leading to the free 2,6-substituted pteridine nucleosides (**10-15**) in 81-96 % yield. Removal of the dimethylaminomethylene group afforded an additional treatment with aqueous ammonia. Reaction of the 3'-O- and 5'-O-unsubstituted building blocks (**10-15**) with dimethoxytrityl chloride in pyridine formed the appropriate 5'-O-tritylated nucleosides (**16-21**)⁴. The 5'-O-substitution was favoured due to the higher reactivity of the primary 5'-OH function, but still 8-19 % of the 3',5'-di-O-tritylated products were isolated after workup and flash chromatography. Finally, the reaction with β -cyanoethoxy-bis-(diisopropylamino)phosphane under 1H-tetrazole catalysis led to the 3'-O-(β -cyanoethyl)-diisopropylphosphoramidites (**22-27**) in high yields⁵. Purification of the phosphoramidite building blocks was achieved by flash chromatography on silica gel giving colourless and yellow foams, suitable for the synthesis of 3'-5' linked oligodeoxynucleotides in solution or on a solid support by a repetitive cycle.

A second series of building blocks for the solid phase synthesis, the 3'-O-hemisuccinates (**28-33**) of the six pteridine nucleosides were prepared by the almost quantitative reaction with succinic anhydride and 4-(dimethylamino)pyridine (DMAP)⁶. **28-33** were subsequently coupled to a special modified LCAMA-CPG [(long chain alkyl)methylamino controlled pore

	R ¹	R ²	
1	H	H	10 16 22 28
2	C ₆ H ₅	H	11 17 23 29
3	H	C ₆ H ₅	12 18 24 30
4	C ₆ H ₅	C ₆ H ₅	13 19 25 31
5	H	CH ₃	14 20 26 32
6	CH ₃	CH ₃	15 21 27 33

	R ¹	R ²
7	H	C ₆ H ₅
8	C ₆ H ₅	C ₆ H ₅
9	H	CH ₃



Synthesis of the monomeric building blocks for oligonucleotide chemistry


glass)] solid support material in the presence of the condensing reagent O-[cyano(ethoxycarbonyl) methylideneamino]-1,1,3,3-teramethyluronium tetrafluoroborate (TOTU) followed by a capping process with Ac_2O /DMAP in pyridine. Loadings between 29 and 39 $\mu\text{mol/g}$ were reached with a 500 Å-CPG material.

Structure. Syntheses of nucleosides by glycosylation of heterocycles typically result in isomeric products and called therefore several chemical and biochemical methods⁷ as well as CD⁸ and NMR⁹ measurements providing more or less suitable information about configurational and conformational parameters. For example, the structural assignment of regioisomers based on the chemical shifts of glycosidic and base protons in the ^1H -NMR spectra, and that of α/β -anomers on the signal pattern of the H-C(1').

For the β -configured pteridine nucleosides (**10-15**) we found in analogy to former investigations^{7c} a characteristic large chemical shift difference $\Delta\delta$ of the $\text{H}_\alpha\text{-C}(2')$ and the $\text{H}_\beta\text{-C}(2')$ resonance in the ^1H -NMR spectra. The value of $\Delta\delta$ (250 MHz) in DMSO-d_6 and CDCl_3 ranges between 0.6 and 0.9 ppm for the β -anomers (**10-15**) whereas the same signals lie fairly close to one another in the α -anomers ($\Delta\delta = 0\text{-}0.1$ ppm). That seems to be an indication of a more favoured and more restricted S-type puckered conformation in the β -anomers (**10-15**) whereby the distance between $\text{H}_\beta\text{-C}(2')$ and the nucleobase is shortened to a minimum. In the α -anomers a more flexible situation is assumed. However, we have to confess, that the solvent dependence of chemical shifts and coupling constants, based on the influence of steric and electronic effects to the conformational equilibria, makes such generalisations questionable.

In accordance to the more reliable results of F. Seela¹⁰ and G. E. Wright¹¹, the two dimensional ROESY ^1H -NMR spectra show typical distance related cross relaxations for the β -configured pteridine nucleosides (**10-15**). In general, the β -anomers display intensive crosspeaks between the protons H-C(1')/ $\text{H}_\alpha\text{-C}(2')$, H-C(1')/H-C(4') and $\text{H}_\beta\text{-C}(2')$ /H-C(3'), which are located in the whole range of N- to S-type conformations on the same side of the sugar moiety. Consequently, only weak crosspeaks between H-C(1') and $\text{H}_\beta\text{-C}(2')$ are obtained because they are positioned on contrary faces.

We also learned from our two dimensional NMR investigations that the absence of ROE interactions between the base and the glycosidic protons points to a preferred *anti*-conformation of the pteridines with respect to the sugar. Therefore the β -glycosidic torsion angle χ , enclosed by C(1')-O(4') and N(8)-C(8a), ranges in analogy to the purine nucleosides¹² between $180 \pm 90^\circ$. Only in the case of **10** and **11** weak crosspeaks of the pteridine substituents H-C(2) and Ph-C(2), respectively, with HO-C(5') and H-C(3') are observed, implicating a higher *syn/anti* glycosidic bond ratio.



600 MHz ROESY ¹H-NMR spectrum of 4-amino-8-(2-deoxy-β-D-ribofuranosyl)-7(8H)-pteridinone (10) in DMSO-d₆.

However, the energy barrier between the *syn* and *anti* conformation is usually low, implying dynamic equilibria which might be more or less directed towards one side. Therefore a statement based on ROE intensities in analogy to the pyrimidine and purine nucleosides¹³ is very difficult. Perhaps, the use of ROE intensities together with other structure constraints leads to a general approach to the conformational analysis.

Acknowledgment. We are thankful to M. Cavegen and Dr. A. Geyer, Universität Konstanz, for the determination and discussion of the two dimensional ROESY ¹H-NMR spectra.

REFERENCES

1. Hawkins M. E.; Pfeleiderer W.; Mazumder A.; Pommier Y. G.; Balis F. M. *Nucleic Acids Res.* **1995**, *23*, 2872.
2. Jungmann O.; Pfeleiderer W. *Tetrahedron Lett.* **1996**, *37*, 8355.
3. Zemplen G.; Gerecs A.; Hadacsy J. *Ber. Dtsch. Chem. Ges.* **1936**, *69*, 1827.
4. Smith M.; Rammler D. H.; Goldberg I. H.; Khorana H. G. *J. Am. Chem. Soc.* **1962**, *84*, 430.
5. Sinah N. D.; Biernat J.; McManus J.; Köster H. *Nucleic Acids Res.* **1984**, *12*, 4539.
6. Gait M. J.; Singh M.; Sheppard R. C.; Edge M. D.; Greene A. R.; Heathcliffe G. R.; Atkinson T. C.; Newton C. R.; Markham A. F. *Nucleic Acids Res.* **1980**, *8*, 1081.
7. a) Mizuno Y.; Ikehane M.; Watanabe K. A.; Suzaki S.; Itoh T. *J. Org. Chem.* **1963**, *28*, 3329; b) Rosemeyer H.; Seela F. *J. Org. Chem.* **1987**, *52*, 5136; c) Cao X.; Pfeleiderer W.; Rosemeyer H.; Seela F.; Bannwarth W.; Schönholzer P. *Helv. Chim. Acta* **1992**, *75*, 1267.
8. Emerson T. R.; Swan R. J.; Ulbricht T. L. V. *Biochemistry* **1967**, *6*, 843.
9. Robins M. J.; Robins R. K. *J. Am. Chem. Soc.* **1965**, *87*, 4934; Nuhn P.; Zschunke A.; Heller D.; Wagner G. *Tetrahedron* **1969**, *25*, 2139; Imbach J. L.; Barascut J. L.; Kam B. L.; Rayner B.; Tamby C.; Tapiero C. *J. Heterocycl. Chem.* **1973**, *10*, 1069; Dea P.; Revankar G. R.; Tolmann R. L.; Robins R. K.; Schweizer M. P. *J. Org. Chem.* **1974**, *39*, 3226; Seela F.; Bussmann W. *Nucleosides & Nucleotides* **1985**, *4*, 391.
10. Rosemeyer H.; Toth G.; Seela F. *Nucleosides & Nucleotides* **1989**, *8*, 587.
11. Gambino J.; Yang T.; Wright G. E. *Tetrahedron* **1994**, *50*, 11363.
12. Sundaralingam M. *Biopolymers* **1969**, *7*, 821.
13. Rosemeyer H.; Toth G.; Golankiewicz B.; Kazimierczuk Z.; Bourgeois W.; Kretschmer U.; Muth H.; Seela F. *J. Org. Chem.* **1990**, *55*, 5784.